Literature DB >> 16498193

Thromboelastography detects inadequate response to abciximab therapy during stent-assisted cerebral aneurysm coil embolization complicated by stroke.

Frederick W Lombard1, Ian J Welsby, Michael J Alexander, Cecil O Borel.   

Abstract

INTRODUCTION: Thromboembolic stroke is the most common severe complication following coil embolization of intracerebral aneurysms, with a 5% incidence of permanent deficits. Despite heparin anticoagulation, rescue therapy with the platelet glycoprotein IIb/IIIa receptor antagonist abciximab may be required. However, we describe a failure of abciximab rescue therapy and discuss the importance of monitoring the variable individual response to abciximab. CASE REPORTS: Two patients underwent stent-assisted cerebral aneurysm coil embolization complicated by thromboembolic stroke. In one patient, abciximab rescue therapy failed and was associated with a poor neurological outcome. Thromboelastography (TEG model 5000; Haemoscope, Skokie, IL) and platelet aggregometry suggested inadequate platelet inhibition, although other tests of platelet function suggested adequate inhibition.
CONCLUSION: We describe a failure of regular-dose abciximab rescue therapy for thromboembolic stroke-complicating stent-assisted cerebral aneurysm coil embolization. The use of TEG to individualize abciximab dosing in this setting may improve patient outcome, as it tracks a pattern of coagulation consistent with the clinical picture.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16498193     DOI: 10.1385/NCC:4:1:032

Source DB:  PubMed          Journal:  Neurocrit Care        ISSN: 1541-6933            Impact factor:   3.210


  18 in total

1.  Rescue treatment of acute parent vessel thrombosis with glycoprotein IIb/IIIa inhibitor during GDC coil embolization.

Authors:  T E Lempert; A M Malek; V V Halbach; C C Phatouros; C F Dowd; R T Higashida
Journal:  Stroke       Date:  1999-03       Impact factor: 7.914

Review 2.  Thrombelastography.

Authors:  N Salooja; D J Perry
Journal:  Blood Coagul Fibrinolysis       Date:  2001-07       Impact factor: 1.276

3.  Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS).

Authors:  M E Bertrand; H J Rupprecht; P Urban; A H Gershlick
Journal:  Circulation       Date:  2000-08-08       Impact factor: 29.690

4.  Caveats about elective coronary stenting.

Authors:  E J Topol
Journal:  N Engl J Med       Date:  1994-08-25       Impact factor: 91.245

5.  Evaluation of coagulation during cardiopulmonary bypass with a heparinase-modified thromboelastographic assay.

Authors:  K J Tuman; R J McCarthy; M Djuric; V Rizzo; A D Ivankovich
Journal:  J Cardiothorac Vasc Anesth       Date:  1994-04       Impact factor: 2.628

6.  "Rescue" utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty.

Authors:  J B Muhlestein; L A Karagounis; S Treehan; J L Anderson
Journal:  J Am Coll Cardiol       Date:  1997-12       Impact factor: 24.094

7.  Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.

Authors:  S R Steinhubl; J D Talley; G A Braden; J E Tcheng; P J Casterella; D J Moliterno; F I Navetta; P B Berger; J J Popma; G Dangas; R Gallo; D C Sane; J F Saucedo; G Jia; A M Lincoff; P Theroux; D R Holmes; P S Teirstein; D J Kereiakes
Journal:  Circulation       Date:  2001-05-29       Impact factor: 29.690

8.  Reduced inhibition by abciximab in platelets with the PlA2 polymorphism.

Authors:  Guy L Wheeler; Gregory A Braden; Paul F Bray; Stanley J Marciniak; Mary Ann Mascelli; David C Sane
Journal:  Am Heart J       Date:  2002-01       Impact factor: 4.749

9.  Clinical experience with the Palmaz-Schatz coronary stent. Initial results of a multicenter study.

Authors:  R A Schatz; D S Baim; M Leon; S G Ellis; S Goldberg; J W Hirshfeld; M W Cleman; H S Cabin; C Walker; J Stagg
Journal:  Circulation       Date:  1991-01       Impact factor: 29.690

10.  Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.

Authors:  Paul A Gurbel; Kevin P Bliden; Bonnie L Hiatt; Christopher M O'Connor
Journal:  Circulation       Date:  2003-06-09       Impact factor: 29.690

View more
  1 in total

1.  Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting.

Authors:  S Prabhakaran; K R Wells; V H Lee; C A Flaherty; D K Lopes
Journal:  AJNR Am J Neuroradiol       Date:  2007-11-07       Impact factor: 3.825

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.